Evonik Creavis’ Post

Very happy to see our research effort finally published in Frontiers in Molecular Biosciences! Check out our work and learn how Clarivate for Life Sciences & Healthcare products, in combination with machine learning techniques, can contibute to expand the current knowledge on #rarediseases

At Pier 23 Labs, we recognize the critical role of clinical trials in the advancement of treatments for conditions like glaucoma. Glaucoma, a leading cause of irreversible blindness worldwide, stands to benefit greatly from advancements in molecular biology and innovative clinical trials. Our team has been working tirelessly on a series of clinical trials, exploring the potential of novel therapeutics in managing intraocular pressure - a key risk factor in glaucoma. These efforts have led to significant progress in our understanding of the disease, bringing us closer to more effective, patient-centric treatments. We have incorporated cutting-edge biotechnology methods such as next-generation sequencing to understand the genetic components of glaucoma, aiding in both diagnosis and therapeutic development. These advancements are a testament to our relentless pursuit of innovation, quality, and precision in every sequence. With Pier 23 Labs, we bring a glimmer of hope to those affected by glaucoma, arming physicians with better diagnostic and management tools. #Glaucoma #ClinicalTrials #Biotechnology #Pier23Labs #PrecisionInEverySequence Learn More >>> 🌐 https://pier23labs.com/

Happy to share our recent work in an incredibly fruitful collaboration with Novo Nordisk. Special thanks for this enjoyable synergy with Vivek Das, PhD, M.Sc. Simon Baumgart Rafael Kramann, MD, PhD Sikander Hayat and all other authors. Our preprint shows an integrative high-resolution map of human atherosclerotic plaques by combining single-cell RNA-seq from multiple studies and novel spatial transcriptomics data from 12 human specimens, highlighing: - Possible recruitment of lymphocytes via different types of endothelial cells - Spatial and cell type specific changes at different stages of atherosclerosis - Migration of vascular smooth muscle cells towards fibromyocytes - Spatially resolved Cell-cell communication in the plaque https://lnkd.in/eX4SCZPd

We're proud sponsors and active participants in the 2023 SLC6A1 Connect International Symposium in Orlando, Florida. Delighted to have Dr. Nianwei Lin representing iXCells as one of the presenters, shedding light on how disease-relevant cell models contribute to the progress in rare neurogenetic disorder research. Missed the event? No worries! Gain exclusive access to Dr. Lin's insightful presentation, exploring practical solutions for rare neurogenetic disorders and potential therapeutic strategies, and stay updated on the latest in neurogenetic research. At iXCells, our commitment extends to rare disease advocacies, researchers, doctors, and the scientific community. 🤝 Our goal to contribute to the future of patient care through personalized drug discovery and translational research. #Biotechnology #Innovation #DrugDiscovery #PersonalizedMedicine #RareDiseases #ResearchandDevelopment #SCL6A1 #GeneEditing #EngineeredCells #CRISPRCas9 #CellModels #STEMCells #LifeSciences #ResearchandDevelopment #rarediseaseawareness #aso

#SpecialIssue #Sarcomas comprise a heterogeneous group of rare and understudied cancers of the connective tissue that disproportionally affect the young. In the following special issue, the main objective was to put the spotlight on recent advances in understanding the pathogenic mechanisms driving sarcomas, and the most promising novel therapeutic avenues that have been investigated through preclinical, translational or clinical research. 👩🔬 Guest Editor: Dr. Emmy D.G. Fleuren 👉 Published papers can be accessed here: https://lnkd.in/dpgYcxdn

🚀 Exciting News from BioVivium Strategies! 🚀 We're thrilled to share a new breakthrough highlighted in our latest blog post: "Unlocking the Potential of ctDNA: Advancing Oncology Clinical Trials." Our Chief Scientific Officer led an innovative Design of Experiment (DOE), utilizing advanced flow cytometry techniques to enhance the viability and functionality of cryopreserved Peripheral Blood Mononuclear Cells (PBMCs). This DOE is pivotal for researchers and clinicians aiming to maximize the effectiveness of immunological assays and cellular therapies. 🔬 Why is this important? DOE methodologies are crucial for optimizing laboratory protocols and therapeutic applications. Our latest project exemplifies how strategic experiment design can lead to significant advancements in biotechnology and patient care. 🌟 What we offer: At BioVivium, we specialize in tailoring DOEs to meet the specific needs of our clients, ensuring precision, efficiency, and reproducibility. Our goal is to empower biotech companies to accelerate their R&D through scientifically sound strategies. Read more about how we're pushing the boundaries of biotech research and check out our services to see how we can support your projects: https://wix.to/piKsuY8 #Biotechnology #FlowCytometry #DOE #BioViviumStrategies #Innovation #ResearchAndDevelopment #newblogpost

Check out our recently published preprint on mapping human atherosclerosis

Listen to Allison Hubel, PhD, Founder and CSO of Evia Bio, give a short description of our Non-DMSO solution at the last CryoChats™ entitled 'Cryopreservation Benefits and Costs of DMSO' on April 17th, 2024. Evia Bio™ is a life science innovation company enabling the growing cell therapy market. We provide new non-DMSO cryopreservation solutions developed by world-leading cryobiologist, Allison Hubel, PhD. We partner with cell therapy companies looking to advance their products to clinical trials and commercialization. Our solutions unlock the full potential of emerging life-saving therapies through the use of all-natural organic compounds to protect the integrity of cells during cryopreservation and patient safety at the point of care. Please visit www.eviabio.com. Join us for our next CryoChats™ entitled "Cryopreservation Clinical Risks" on June 12, 2024 at 1PM CDT. Register Here: https://lnkd.in/gUXVHa83 6/12 Assessing Operational Risk and Clinical Impact 7/31 Cryopreservation Scaling

It is indeed an honour to present our poster on the 15th Wädenswil Day of Life Sciences: 6th June 2024 at the symposium “Competencies in Drug Discovery” in Zurich, titled: “Strategic in silico pipeline for PROTAC screening: validation with CRBN-RN6-BRD4”.  We showcase our integrated computational & bioinformatics pipeline-guided evaluation of therapeutic targets and design of PROTAC molecules with emphasis on linker chemistry. PROTACs are the hottest therapeutic modalities to tackle undruggable targets where SMs fail to show the expected therapeutic outcome. BRD4 is a classic example of a potential anti-cancer target; PROTAC-mediated targeting of BRD4 has proven beneficial over SMs. Our pipeline aids in the identification of an optimal preclinical model for efficacy and safety/tox study. We provide a way forward in predicting the impact of deubiquitinating to estimate the therapeutic area-specific efficacy of the designed PROTACs.    We are excited to meet you at the poster session!  To download the poster,click: https://lnkd.in/gAEuSc5j     #ZHAW #Insilico #Bioinformatics #Cancer #PROTAC #DrugDiscovery #Integratedpipeline #TCGLifeSciences #DataScience #BRD4 #DUB #Efficacy #Toxicity    Sohini Basu, Snigdha Patel, Nivedita Dharwar, Anupama Goyal, Sonali Das, Joaquim Figueiredo

We present here an insightful informatics based pipeline for prediction of PROTAC therapeutic modality outcome.